BACKGROUND: The chemokine receptor polymorphisms CCR5Delta32, CXCL12 3'A, CCR2-64I and CCR5-59029 G/A have been demonstrated to affect HIV-1 infection and progression. OBJECTIVE: We studied the impact of the above polymorphisms on the effectiveness of a 30-month treatment with highly active antiretroviral therapy (HAART) in 149 HIV-1 patients. STUDY DESIGN: We stratified the patients according to CD4 CDC criteria and applied Kaplan-Meier analysis using the following end-point criteria: (a) the time from HAART initiation to undetectable viral load (VL) counts (VL<50 copies/ml), (b) the duration of undetectable VL status and (c) the time required for CD4+ T-cell counts to pass over the 500 cells/ml threshold. RESULTS: Our results in the second group (CD4 201-500) revealed that patients with the CCR2-64I allele achieved undetectable VL counts at 3.5+/-0.48 months as compared to 10.26+/-1.42 months in the control group (p=0.018). The VL remained undetectable for 28+/-2 months, in contrast to 20+/-2 months in the control group (p=0.048). Patients carrying CXCL12 3'A restored the CD4 population faster than the control group (9+/-2 and 14+/-2 months, respectively, p=0.023). The CCR5Delta32 and CCR5-59029 G/A alleles did not appear to affect the parameters studied. CONCLUSIONS: Our results suggest that patients carrying either CCR2-64I or CXCL12 3'A have a more favorable prognosis during HAART treatment.
BACKGROUND: The chemokine receptor polymorphisms CCR5Delta32, CXCL12 3'A, CCR2-64I and CCR5-59029 G/A have been demonstrated to affect HIV-1 infection and progression. OBJECTIVE: We studied the impact of the above polymorphisms on the effectiveness of a 30-month treatment with highly active antiretroviral therapy (HAART) in 149 HIV-1patients. STUDY DESIGN: We stratified the patients according to CD4 CDC criteria and applied Kaplan-Meier analysis using the following end-point criteria: (a) the time from HAART initiation to undetectable viral load (VL) counts (VL<50 copies/ml), (b) the duration of undetectable VL status and (c) the time required for CD4+ T-cell counts to pass over the 500 cells/ml threshold. RESULTS: Our results in the second group (CD4 201-500) revealed that patients with the CCR2-64I allele achieved undetectable VL counts at 3.5+/-0.48 months as compared to 10.26+/-1.42 months in the control group (p=0.018). The VL remained undetectable for 28+/-2 months, in contrast to 20+/-2 months in the control group (p=0.048). Patients carrying CXCL12 3'A restored the CD4 population faster than the control group (9+/-2 and 14+/-2 months, respectively, p=0.023). The CCR5Delta32 and CCR5-59029 G/A alleles did not appear to affect the parameters studied. CONCLUSIONS: Our results suggest that patients carrying either CCR2-64I or CXCL12 3'A have a more favorable prognosis during HAART treatment.
Authors: Rajeev K Mehlotra; Vinay K Cheruvu; Melinda J Blood Zikursh; Rebekah L Benish; Michael M Lederman; Robert A Salata; Barbara Gripshover; Grace A McComsey; Michelle V Lisgaris; Scott Fulton; Carlos S Subauste; Richard J Jurevic; Chantal Guillemette; Peter A Zimmerman; Benigno Rodriguez Journal: J Infect Dis Date: 2011-07-15 Impact factor: 5.226
Authors: Noemi B Hall; Shannon E Bruse; Bangan John; Rajeev K Mehlotra; Melinda J Blood Zikursh; Catherine M Stein; Peter M Siba; Peter A Zimmerman Journal: Infect Genet Evol Date: 2015-09-28 Impact factor: 3.342
Authors: Susan M Thomas; Doris B Tse; D Scott Ketner; Gemma Rochford; Daniel A Meyer; David D Zade; Perry N Halkitis; Arthur Nádas; William Borkowsky; Michael Marmor Journal: AIDS Date: 2006-09-11 Impact factor: 4.177
Authors: Sher L Hendrickson; Lisa P Jacobson; George W Nelson; John P Phair; James Lautenberger; Randall C Johnson; Lawrence Kingsley; Joseph B Margolick; Roger Detels; James J Goedert; Stephen J O'Brien Journal: J Acquir Immune Defic Syndr Date: 2008-07-01 Impact factor: 3.731
Authors: Clara Restrepo; Mónica Gutierrez-Rivas; Yolanda M Pacheco; Marcial García; Julià Blanco; Luz M Medrano; María A Navarrete-Muñoz; Félix Gutiérrez; Pilar Miralles; David Dalmau; Juan Luis Gómez; Miguel Górgolas; Alfonso Cabello; Salvador Resino; José M Benito; Norma Rallón Journal: PLoS One Date: 2019-03-28 Impact factor: 3.240